2021On March 25, cardiac electrophysiology company Synaptic Medical (hereinafter referred to as "Xinnopu Medical") completed a nearly $60 million (approximately RMB 392 million) Series G financing round, led by Huagai Capital, with follow-on investments from YuanBio Venture Capital and existing shareholder SIG. HAOYUE CAPITAL served as the exclusive financial advisor for this round. The proceeds will be used to further accelerate the expansion of its cardiac electrophysiology product portfolio.
According to official information, Sinuopu Medical2005was founded in Minnesota, USA, in,2007Established a wholly-owned subsidiary in Beijing in [Year], it is a cardiac electrophysiology enterprise driven by both innovation and internationalization, currently encompassing over ten product lines across three major categories: diagnostic catheters, therapeutic catheters, and puncture devices, with multiple products having obtained U.S.FDA, European UnionCE, and JapanPMDAregistration certificate, which is highly beneficial for expanding overseas markets and driving sustained growth in overseas revenue，`Local promotion and sales`, gaining recognition from local experts.In China, Xinnuopu productsSales coverage across China reaches nearly800Hospital，Meanwhile, in multiple competitions in China, Synaptic Medical's renal denervation technology for hypertension has also been recognized by numerous experts in China, in2019Won the Excellence Award at the China Medical Device Innovation and Entrepreneurship Competition.In the rapidly growing electrophysiology sector, Xinuopu Medical will leverage its globally-oriented R&D team to continuously and rapidly develop innovative products. Driven by a deep understanding of clinical application pain points, the company will deliver high-performance devices and accelerate its pace of international expansion.
Synaptic Medical Related Products
The cardiac electrophysiology industry primarily focuses on the diagnosis and treatment of tachyarrhythmia-related diseases, such as atrial fibrillation. Atrial fibrillation is the most common sustained arrhythmia and a major risk factor for cardioembolic stroke. It is also closely associated with the pathogenesis of heart failure, hypertension, and other conditions, representing a critical challenge that urgently needs to be addressed in the global field of cardiology.
As people's awareness of atrial fibrillation、HypertensionDengxin# Common Vascular ConditionsDriven by the growing emphasis on disease management and the accelerating aging population, the electrophysiology sector is exhibiting a trend of rapid development, with major international mainstream markets such as Europe and the United States maintaining double-digit annual growth. As the electrophysiology market with the greatest global potential, China's market size is approaching...50hundred million yuan, with a compound annual growth rate exceeding30%，Expected2024In [Year], the global electrophysiology market approached $10 billion.
However, given the complexity of surgical procedures, the long learning curve for physicians, and the high performance requirements for electrophysiology (EP) devices and consumables, the global market has long been monopolized by industry giants such as Johnson & Johnson, Abbott, and Medtronic, and the Chinese market is no exception. Currently, these international giants still account for over 90% of the domestic market, leaving domestic brands with a low market share.Based on this, from its very inception, Synaptic Medical committed to collaborating with top domestic and international experts in R&D and innovation, forging its own original product development path characterized by unique design philosophies, distinctive technical features, and independent intellectual property rights.2020In [Year], Synaptic Medical established an innovation R&D center in California, USA, working in close synergy with its Chinese R&D team.
About the China Medical Device Innovation and Entrepreneurship Competition:
The China Medical Device Innovation and Entrepreneurship Competition is a national medical device industry innovation and entrepreneurship competition organized by the Medical Device Industry Technology Innovation Strategic Alliance. The competition and Innovation Week activities have sinceBy 2018, the competition had been successfully held for three editions, soliciting 283, 607, and 665 innovative medical device R&D projects from domestic and international sources, respectively. The event and its supporting activities attracted participation from over 1,200 enterprises, along with innovation service and investment institutions. Over 30,000 attendees observed the proceedings on-site, with guidance provided by leaders from various ministries, academicians, and more than 100 authoritative experts from regulatory agencies and the industry. Across the three finals, a total of 167 projects were awarded first, second, and third prizes. According to follow-up statistics compiled six months post-competition, cumulative financing exceeded RMB 4.2 billion. Furthermore, several projects subsequently secured research grants from national ministries, provincial and municipal governments, and the military, as well as various other competition awards. The competition has effectively accelerated the technology transfer and commercialization of medical device innovations, earning consistent acclaim from all stakeholders.
The 4th China Medical Device Innovation and Entrepreneurship CompetitionCategory Tracks and Special TracksComing Soonsuccessively inHeld in various locations,WelcomeVarious regionsInnovative teams, relevant enterprises, research institutes, innovation service and investment institutions, as well as hospitals and clinical expertsarrive on site# Watch Match! For detailed announcements, please refer to the official competition website.www.cmddec.cn and the “Medical Device Innovation Network” WeChat Official Account!
Source: Medical Device Industry Technology Innovation Strategic Alliance / PEdaily
Follow our WeChat Official Account
Get More Information
